Pharmacokinetics of diazepam in disordered liver function

Area of Science:

• Pharmacokinetics
• Hepatology
• Drug Metabolism

Background:

• Diazepam is a commonly prescribed benzodiazepine.
• Liver disease can significantly alter drug metabolism and elimination.
• Understanding diazepam pharmacokinetics in cirrhosis is crucial for patient management.

Purpose of the Study:

• To investigate the plasma elimination of diazepam in patients with cirrhosis of the liver.
• To compare diazepam pharmacokinetics between cirrhotic patients and healthy controls.
• To assess the correlation between diazepam clearance and indicators of liver function.

Main Methods:

• Intravenous administration of 10 mg diazepam to nine patients with cirrhosis and four healthy controls.
• Analysis of plasma elimination curves using a two-compartment model.
• Correlation analysis with liver function tests including galactose elimination capacity, serum albumin, and prothrombin.

Main Results:

• The mean biological half-life (T/2) of diazepam was significantly prolonged in cirrhotic patients (164 hours) compared to controls (32.1 hours).
• Plasma clearance of diazepam did not correlate with quantitative (galactose elimination capacity) or semiquantitative (serum albumin, prothrombin) measures of liver function.
• Individual variability in diazepam elimination was observed within the cirrhotic group.

Conclusions:

• Diazepam elimination is markedly impaired in patients with liver cirrhosis.
• Plasma clearance of diazepam is not a reliable indicator of hepatic metabolic rate in cirrhosis due to complex drug kinetics.
• Further research is needed to elucidate the specific mechanisms underlying altered diazepam metabolism in liver disease.